Sversa medicina - Company finances
|
EUR
|
2021
From: 2021-09-10
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 101,339 | 432,782 | 537,158 | 474,457 | 719,298 |
| Profit before tax | - | 17,697 | 59,666 | 27,017 | 103,200 |
| Net profit | 17,903 | 15,036 | 50,911 | 23,152 | 86,548 |
| Equity | 20,403 | 35,439 | 82,350 | 79,611 | 154,394 |
| Liabilities | 33,737 | 109,884 | 144,792 | 88,077 | 151,443 |
| Non-current assets | 0 | 0 | 20,708 | 16,700 | 23,841 |
| Current assets | 54,140 | 145,323 | 206,295 | 150,817 | 281,435 |
| Total assets | 54,140 | 145,323 | 227,003 | 167,517 | 305,276 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 49,701 | 75,687 | 64,029 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +327.1% | +24.1% | -11.7% | +51.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 33.1% | 10.3% | 22.4% | 13.8% | 28.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 87.7% | 42.4% | 61.8% | 29.1% | 56.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 17.7% | 3.5% | 9.5% | 4.9% | 12.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 4.1% | 11.1% | 5.7% | 14.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.7 | 3.1 | 1.8 | 1.1 | 1.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 50,670 | 207,739 | 268,579 | 237,229 | 359,649 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Sversa medicina - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-16 | 2026-07-17 | 1585.36 |
| 2026-06-17 | 2026-07-14 | 0.40 |
| 2026-06-16 | 2026-06-16 | 1815.36 |
| 2026-06-11 | 2026-06-15 | 0.40 |
| 2026-05-27 | 2026-06-08 | 0.40 |
Sversa medicina - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-21 | 2026-02-21 | 7.0 |
| 2026-01-01 | 2026-01-05 | 0.64 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Sversa medicina, UAB (code 305895602), is a private limited liability company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €719.3K and net profit of €86.5K, up from €474.5K revenue and €23.2K net profit in 2024. This followed a decline in 2024 from 2023, when revenue was €537.2K and net profit €50.9K. The 2025 profit margin improved to 12.0% from 4.9% in 2024 and 9.5% in 2023, showing a stronger earnings profile. Balance sheet size also expanded in 2025, with total assets of €305.3K, equity of €154.4K and liabilities of €151.4K. Equity represented 50.6% of assets, and the debt-to-equity ratio was 0.98. Asset turnover reached 2.36x, indicating efficient use of the asset base. Return on equity was 56.1% and return on assets 28.4%. Revenue per employee was €359.6K, and profit per employee was €43.3K, pointing to solid productivity in 2025.